Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PARL | Q9H300 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8328565 | 1.00 | ACHE (0.55) | ACHEMMP2EPHX2AKR1C3ALDH1A1 | |
| SCHEMBL2961151 | 0.96 | ACHE (0.52) | ACHEMMP2EPHX2AKR1C3FAAH | |
| SCHEMBL8319432 | 0.96 | ACHE (0.52) | ACHEMMP2EPHX2AKR1C3FAAH | |
| SCHEMBL13201349 | 0.94 | ACHE (0.49) | ACHEMMP2EPHX2AKR1C3FAAH | |
| SCHEMBL13201340 | 0.87 | MMP2 (0.53) | ACHEMMP2EPHX2AKR1C3MMP9 | |
| SCHEMBL13201328 | 0.84 | CA9 (0.52) | ACHEMMP2EPHX2MMP9 | |
| SCHEMBL2964063 | 0.84 | PSEN1 (0.43) | ACHEMMP2EPHX2ALDH1A1LMNA | |
| SCHEMBL8320723 | 0.84 | PSEN1 (0.43) | ACHEMMP2EPHX2ALDH1A1LMNA | |
| SCHEMBL8327403 | 0.84 | TDP1 (0.41) | ACHEALDH1A1LMNAHTT | |
| SCHEMBL8320725 | 0.84 | EPHX2 (0.42) | ACHEEPHX2AKR1C3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772270-B2 | Imino acid derivatives as inhibitors of matrix metalloproteinases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| EP-1585728-B1 | IMINO ACID DERIVATIVES FOR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-02-24 | — | — | EP | disclosed |
| US-20060252752-A1 | Octahydrocyclopenta[b]pyrrole-sulfonamide-2-carboxylic acid derivatives; reduced side effects | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| EP-1585728-A1 | IMINO ACID DERIVATIVES FOR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | Aventis Pharma Deutschland GmbH (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20050004166-A1 | Imino acid derivatives as inhibitors of matrix metalloproteinases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
| WO-2004060874-A1 | IMINO ACID DERIVATIVES FOR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004166-A1 | Imino acid derivatives as inhibitors of matrix metalloproteinases | MMP9, MMP1, MMP25 | ACHE 2003/4885MMP2 5/4885EPHX2 826/4885 |
| US-20060252752-A1 | Octahydrocyclopenta[b]pyrrole-sulfonamide-2-carboxylic acid derivatives; reduced side effects | SULT2A1, ADCYAP1R1, SULT1A1 | ACHE 4006/4885MMP2 3817/4885EPHX2 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.